Literature DB >> 11156421

Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.

S Mustjoki1, N Sidenius, C F Sier, F Blasi, E Elonen, R Alitalo, A Vaheri.   

Abstract

The importance of plasminogen activation, mediated by urokinase (uPA) and its receptor (uPAR), is well established in many physiologica and pathological processes, such as in cell migration and tumor-cell invasion. Recently, additional functions have been described for uPA and uPAR, particularly in cell adhesion and chemotaxis. The amounts of uPA and uPAR in various tumor types and in the plasma/serum samples of cancer patients have been shown to correlate with survival prognosis, indicating the relevance of these molecules in malignancy. We previously showed that in acute myeloid leukemia, a high level of plasma soluble uPAR (suPAR) at diagnosis correlates with poor response to chemotherapy. However, in this case, as in other cancers, the origin of suPAR is unknown. Therefore, we have now analyzed uPAR in cells, plasma, and urine of patients with acute leukemia (n = 35) at 0, 5, 14, 28, and 56 days after start of chemotherapy. In response to cytotoxic treatment, suPAR levels decreased rapidly, and the decreasing plasma suPAR (p-suPAR levels correlated highly with decreasing numbers of circulating tumor cells, suggesting that the elevated p-suPAR was produced by circulating tumor cells. Moreover, the p-suPAR level appeared to correlate with the amount of uPAR in tumor cell lysates at diagnosis. Our results also show for the first time that in lysates of circulating tumor cells, studied by immunoprecipitation and immunoblotting, uPAR was partly in fragmented form, whereas only full-length uPAR was found in normal leukocytes. We also detected fragmented suPAR in peripheral blood plasma, in urine, and especially in the plasma compartment of bone-marrow aspirates of acute myeloid leukemia patients, in a pattern differing considerably from that found in healthy individuals. Because proteolytic cleavage of uPAR induces a potent chemotactic response in vitro, it is possible that these fragments may play a role in the pathophysiology of acute leukemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156421

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Authors:  Paola Llinas; Marie Hélène Le Du; Henrik Gårdsvoll; Keld Danø; Michael Ploug; Bernard Gilquin; Enrico A Stura; André Ménez
Journal:  EMBO J       Date:  2005-04-07       Impact factor: 11.598

2.  Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.

Authors:  Jie Shen; Qing Wang; Juan Wang; Guo-Hong Su; Juan Wang; Sheng-Hu Guo; Y A Liu; Zheng Wu; Rong-Feng Liu; Xing Li; Xiao-Jin Guo; Jing Cao; Yue-Hua Zhang; Zhi-Yu Wang
Journal:  Oncol Lett       Date:  2015-08-14       Impact factor: 2.967

3.  Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.

Authors:  T K Outinen; S Mäkelä; R Huttunen; N Mäenpää; D Libraty; A Vaheri; J Mustonen; J Aittoniemi
Journal:  J Intern Med       Date:  2014-05-14       Impact factor: 8.989

4.  The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.

Authors:  M Resnati; I Pallavicini; J M Wang; J Oppenheim; C N Serhan; M Romano; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

5.  Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study.

Authors:  Paulo Rabna; Andreas Andersen; Christian Wejse; Ines Oliveira; Victor Francisco Gomes; Maya Bonde Haaland; Peter Aaby; Jesper Eugen-Olsen
Journal:  Inflammation       Date:  2010-12       Impact factor: 4.092

6.  Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells.

Authors:  Marc Tjwa; Nicolai Sidenius; Rute Moura; Sandra Jansen; Koen Theunissen; Annapaola Andolfo; Maria De Mol; Mieke Dewerchin; Lieve Moons; Francesco Blasi; Catherine Verfaillie; Peter Carmeliet
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

7.  Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Authors:  Boris K Pliyev; Mikhail Yu Menshikov
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

8.  Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor.

Authors:  Line V Hansen; Henrik Gårdsvoll; Boye S Nielsen; Leif R Lund; Keld Danø; Ole N Jensen; Michael Ploug
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

9.  Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.

Authors:  A F Lomholt; G Høyer-Hansen; H J Nielsen; I J Christensen
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

10.  Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.

Authors:  H Taubert; P Würl; T Greither; M Kappler; M Bache; C Lautenschläger; S Füssel; A Meye; A W Eckert; H-J Holzhausen; V Magdolen; M Kotzsch
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.